SOPHiA GENETICS partners with AstraZeneca to develop global companion diagnostics for cancer therapies.

SOPHiA GENETICS announced a multi-year collaboration with AstraZeneca to develop and commercialize two companion diagnostics supporting precision oncology therapies. The partnership will focus on creating decentralized diagnostics for solid tumors and blood cancers, enabling local labs worldwide to perform standardized tests from day one of drug approval. This effort aims to improve patient access to targeted treatments by combining AI-driven biomarker detection with rapid deployment through SOPHiA GENETICS's global data platform. The collaboration supports advancing precision medicine by connecting healthcare institutions globally to enhance clinical decision-making and patient outcomes.